Home » Stocks » ALLK

Allakos Inc. (ALLK)

Stock Price: $80.91 USD -0.93 (-1.13%)
Updated Jul 29, 2021 11:42 AM EDT - Market open
Market Cap 4.39B
Revenue (ttm) n/a
Net Income (ttm) -181.21M
Shares Out 53.19M
EPS (ttm) -3.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $80.91
Previous Close $81.83
Change ($) -0.93
Change (%) -1.13%
Day's Open 81.98
Day's Range 80.67 - 83.35
Day's Volume 153,238
52-Week Range 73.75 - 157.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

Other stocks mentioned: AFMD, DCPH
1 week ago - The Motley Fool

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --

1 month ago - GlobeNewsWire

Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

1 month ago - Zacks Investment Research

45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodeniti...

2 months ago - GlobeNewsWire

Bear Of The Day: Allakos (ALLK)

2 months ago - Zacks Investment Research

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: HZNP, IBRX, IMAB, MNMD, SAGE, SWTX
2 months ago - InvestorPlace

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil...

3 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, EBS, EOLS, GBIO, RDUS ...
5 months ago - 24/7 Wall Street

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

7 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

8 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell r...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

9 months ago - GlobeNewsWire

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and web...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

9 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related dise...

11 months ago - GlobeNewsWire

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the...

1 year ago - GlobeNewsWire

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-r...

1 year ago - GlobeNewsWire

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment --

1 year ago - GlobeNewsWire

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease -- -- Management to host conference call and webcast today at 5:00 pm ET --

1 year ago - GlobeNewsWire

-- Management to host conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antol...

1 year ago - GlobeNewsWire

Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma

1 year ago - Seeking Alpha

Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high.

1 year ago - Market Watch

REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today anno...

1 year ago - GlobeNewsWire

Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.

Other stocks mentioned: GH, TWST
1 year ago - The Motley Fool

Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.

1 year ago - The Motley Fool

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Other stocks mentioned: VRTX, BHVN, FOLD, JAZZ
1 year ago - 24/7 Wall Street

As of late, it has definitely been a great time to be an investor Allakos.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for August 9th

Other stocks mentioned: BURBY, CSV, GAIA
1 year ago - Zacks Investment Research

About ALLK

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headqu... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 2018
CEO
Robert Alexander
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 148.67, which is an increase of 83.76% from the latest price.

Price Target
$148.67
(83.76% upside)
Analyst Consensus: Buy